WilmerHale Reps Cydan in Raising $34M to Accelerate New Treatments for Rare Genetic Diseases

• 10.19.2017

Cydan, the first orphan drug accelerator dedicated to advancing therapies that improve the lives of patients with rare genetic diseases, announced a new round of financing, raising a committed total of $34 million to advance the company's efforts to create new and innovative therapies for patients living with rare genetic diseases. The proceeds from this round of financing will fund Cydan II, Inc., continuing the mission of Cydan Development, Inc.

The WilmerHale team representing Cydan included Gary Schall, Stephanie Singer and Bill Caporizzo.

Read Cydan's press release for more information.